Page last updated: 2024-12-06

inproquone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Inproquone is a synthetic, quinoline-based compound that has been investigated for its potential therapeutic applications in various areas, including cancer, inflammation, and neurodegenerative diseases. Its synthesis involves a multi-step process, often starting with readily available starting materials. Inproquone has demonstrated a range of pharmacological effects, including anti-inflammatory, antioxidant, and antiproliferative activities. It is believed to exert its effects through modulation of various cellular pathways, such as the NF-κB signaling pathway. Inproquone is studied for its potential to inhibit tumor growth and reduce inflammation, leading to clinical trials for cancer therapy, particularly for leukemia and solid tumors. The compound also shows promise in reducing neurological damage caused by ischemia and stroke. However, further research is needed to fully understand its mechanism of action, optimize its therapeutic potential, and evaluate its safety and efficacy for clinical use.'

inproquone: major descriptor (78-80); replaced major descriptor Bayer E39 (63-77); on-line search AZIRINES (66-80); Index Medicus search Bayer E39 (63-77), INPROQUONE (78-80) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71627
CHEMBL ID462220
SCHEMBL ID2039769
MeSH IDM0086934

Synonyms (44)

Synonym
2,5-diazirino-3,6-dipropoxy-p-benzoquinone
di-(n-propoxy)-2,5 di-(ethyleneimino)-3,6 benzoquinone-1,4
2,5-bis(ethyleneimino)-3,6-dipropoxy-1,4-benzoquinone
2,5-bis(ethyleneimino)-3,6-dipropoxy-p-benzoquinone
brn 0286633
inprochonum
2,5-cyclohexadiene-1,4-dione, 2,5-bis(1-aziridinyl)-3,6-dipropoxy-
2,5-di-n-propoxy-3,6-bis-aethyleniminobenzochinon-1,4 [german]
cytostatika
nsc 17261
inproquonum [inn-latin]
6870 rp
p-benzoquinone, 2,5-bis(1-aziridinyl)-3,6-dipropoxy-
inproquone [inn:ban]
improcuona [inn-spanish]
ai3-26324
zytostatika
436-40-8
p-benzoquinone,5-bis(1-aziridinyl)-3,6-dipropoxy-
cytostaticum
nsc17261
bayer e 39
rp 6870
inproquone
e 39
nsc-17261
2,4-dione, 2,5-bis(1-aziridinyl)-3,6-dipropoxy-
2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione
rp-6870
CHEMBL462220
inprochone
improcuona
unii-c6y700v0m4
5-20-01-00075 (beilstein handbook reference)
c6y700v0m4 ,
inproquonum
2,5-di-n-propoxy-3,6-bis-aethyleniminobenzochinon-1,4
inproquone [inn]
e-39 (inproquone)
SCHEMBL2039769
DTXSID00195884
nsc 17261;e 39;rp 6870
Q27275266
AKOS040752082
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409947Inhibition of human recombinant MAOB at 1 mM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409952Inhibition of human brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (97.78)18.7374
1990's0 (0.00)18.2507
2000's1 (2.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (97.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]